L. Zhong

发表

Systems Biology Modeling Reveals a Possible Mechanism of the Tumor Cell Death upon Oncogene Inactivation in EGFR Addicted Cancers

Yu-Quan Wei, Shi-Dong Luo, Sheng-Yong Yang, 2011, PloS one.

Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met.

Jian-Ping Zhou, You-Li Pan, L. Zhong, 2011, European journal of medicinal chemistry.

X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.

L. Zhong, Guo‐Bo Li, Ling-Ling Yang, 2018, European journal of medicinal chemistry.

Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY‐1816, in pancreatic ductal adenocarcinoma

L. Zhong, Sheng-yong Yang, Jun Zou, 2019, Cancer science.

SKLB-287, a novel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model.

L. Zhong, Mingwu Zheng, S. Ma, 2014, Neoplasma.

Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer

Yiguo Hu, Xin Chen, L. Zhong, 2017, Oncotarget.

Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.

L. Zhong, Yuquan Wei, Sheng-yong Yang, 2015, Journal of medicinal chemistry.

Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors.

L. Zhong, Shuang-Jiang Ma, Lin-Li Li, 2015, Bioorganic & medicinal chemistry letters.

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer

L. Zhong, Lin-Li Li, Yuquan Wei, 2015, Molecular Cancer Therapeutics.

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

L. Zhong, R. Zheng, Z. Cao, 2012, Leukemia.

Arginine Methyltransferase 1 in the Nucleus Accumbens Regulates Behavioral Effects of Cocaine.

L. Zhong, Sheng-yong Yang, X. Cen, 2015, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.

Yong Xu, Shan Feng, L. Zhong, 2012, Journal of medicinal chemistry.

Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors.

J. Bao, L. Zhong, Xin Long, 2018, Organic and biomolecular chemistry.

SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML

L. Zhong, Shuang-Jiang Ma, Lin-Li Li, 2015, Scientific Reports.

A preclinical evaluation of a novel multikinase inhibitor, SKLB‐329, as a therapeutic agent against hepatocellular carcinoma

L. Zhong, Lin-Li Li, Yuquan Wei, 2014, International journal of cancer.

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

L. Zhong, Sheng-yong Yang, Chenyu Tian, 2021, Signal Transduction and Targeted Therapy.

SC-535, a Novel Oral Multikinase Inhibitor, Showed Potent Antitumor Activity in Human Melanoma Models

Xin Chen, L. Zhong, P. Ji, 2013, Cellular Physiology and Biochemistry.

Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.

Yu-Quan Wei, Yong Xu, Ren-Lin Zheng, 2012, Journal of medicinal chemistry.

SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

Yong Xu, Yang Yu, Xin Chen, 2012, Molecular Cancer Therapeutics.

Preclinical Development SKLB 1206 , a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T 790 M Mutants , ErbB 2 , ErbB 4 , and VEGFR 2 , Displays Potent Antitumor Activity Both In Vitro and In Vivo

Shan Feng, Shi-Dong Luo, You-Li Pan, 2012 .

A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method

Hui Zhang, Lei Zhong, Chang-Ying Ma, 2011, Comput. Biol. Medicine.

A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer

Yuzong Chen, You-Li Pan, L. Zhong, 2014, Molecular Cancer Therapeutics.

LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors.

Guo-Bo Li, Ling-Ling Yang, L. Zhong, 2015, European journal of medicinal chemistry.

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.

L. Zhong, Lin-Li Li, Yuquan Wei, 2016, Journal of medicinal chemistry.

Anti-oral Squamous Cell Carcinoma Effects of a Potent TAZ Inhibitor AR-42

P. Ji, L. Zhong, Si Wang, 2020, Journal of Cancer.

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.

Huan-Zhang Xie, Sheng-Yong Yang, Shan Feng, 2012, Journal of molecular graphics & modelling.

Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.

Takayoshi Suzuki, L. Zhong, Sheng-yong Yang, 2016, Bioorganic & medicinal chemistry letters.

A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer

Yuzong Chen, You-Li Pan, L. Zhong, 2014, Molecular Cancer Therapeutics.

LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors.

L. Zhong, Shuang-Jiang Ma, Ling-Ling Yang, 2015, European journal of medicinal chemistry.